About Zembrace® SymTouch®

Sumatriptan is proven efficacious with a well defined safety profile.1

When timing is everything

Whether it’s waking up with a migraine or experiencing rapid-onset pain, patients want relief—fast.1,2

Fast1,2

Patients may begin to feel migraine pain relief in as little as 10 minutes (17% of patients vs. 5% for placebo).*

Powerful1

~50% of patients experienced migraine pain relief 30 minutes after administration (47% vs. 15% for placebo).*

Simple

A convenient, ready-to-use auto-injector with:

  • A concealed 29 G needle3
  • A discreet, compact design1
  • No refrigeration needed†

60% of patients experienced migraine pain relief 2 hours after administration (vs. 21% for placebo).1 Results from a single-attack, parallel group design study, where six different doses of sumatriptan injection, including 3 mg, were compared (n=30 in each group) with placebo (n=62).

*Time to onset and degree of pain relief varies by patient.
†Store between 68°F and 77°F. Excursions permitted between 59°F and 86°F.

Zembrace® SymTouch® offers the lowest dose in a sumatriptan auto-injector.3

Minutes matter

Proportion of patients with migraine pain relief by time with a 3 mg dose of sumatriptan injection (n=30).1 ‡

3 mg dose of sumatriptan
Placebo
10 mins
17%
5%
30 mins
47%
15%
60 mins
57%
24%
2 hours
60%
21%

‡Results from a single-attack, parallel group design study, where six different doses of sumatriptan injection, including 3 mg, were compared (n=30 in each group) with placebo (n=62).

Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine treated, reconsider the diagnosis before Zembrace® SymTouch® is administered to treat subsequent attacks. Zembrace® SymTouch® is not indicated for the prevention of migraine attacks, and is contraindicated in patients with a history of hemiplegic or basilar migraines.

Committed to providing more

Upsher-Smith Laboratories, LLC takes pride in providing attentive customer service, having strong industry relationships and being dedicated to uninterrupted supply.

Zembrace® SymTouch® continues our commitment to ensure you have a variety of medication options that can address the unique needs of migraine patients.

Want more information?

Sign up today to learn more about Zembrace® SymTouch®.

    Note: This registration form is intended for healthcare providers only.

    *All fields required.


    Privacy Policy and Authorization

    By clicking the submit button below, you consent to the use by Upsher-Smith Laboratories, LLC and its third parties of the information you have provided to periodically send you information about Zembrace® SymTouch® or other products and promotions.

    Upsher-Smith Laboratories, LLC and its third parties use the information you provide for legitimate business purposes only and will not sell, share, or otherwise distribute your personal information to third parties. By joining, you acknowledge that your consent to receive automated messages is not required as a condition to purchase goods and services.


    References:

    1. Zembrace SymTouch [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: February 2021.
    2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276
    3. Data on file. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2021.